Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 12
Submit an article Journal homepage
595
Views
12
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy

Hiromichi TakahashiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; ;Division of Laboratory Medicine, Department of Pathology of Microbiology, Nihon University School of Medicine, Tokyo, Japan;
,
Katsuhiro MiuraDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; Correspondence[email protected] [email protected]
,
Masaru NakagawaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
,
Masahiko SugitaniDepartment of Pathology, Nihon University School of Medicine, Tokyo, Japan
,
Yusuke AmanoDepartment of Pathology, Nihon University School of Medicine, Tokyo, Japan
,
Daisuke KuritaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
,
Masashi SakagamiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
,
Shimon OhtakeDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
,
Yoshihito UchinoDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
,
Hitomi KodairaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
,
Noriyoshi IriyamaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
,
Sumiko KobayashiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
,
Atsuko HojoDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
,
Yujin KobayashiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
,
Yukio HirabayashiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
,
Machiko KusudaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
,
Yoshihiro HattaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; Correspondence[email protected] [email protected]
,
Tomohiro NakayamaDivision of Laboratory Medicine, Department of Pathology of Microbiology, Nihon University School of Medicine, Tokyo, Japan;
&
Masami TakeiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
show all
Pages 2784-2790 | Received 01 Oct 2015, Accepted 08 Mar 2016, Published online: 13 Apr 2016
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Co-expression of MYC and BCL2 proteins in diffuse large B-cell lymphoma (DLBCL), or ‘double-expressor lymphoma’ (DEL), results in poor patient prognosis, but the significance of DEL when aggressive treatments are applied remains uncertain. We performed a retrospective analysis of 40 patients with de novo DLBCL, who were categorized as being at high/high-intermediate risk according to the age-adjusted International Prognostic Index. Patients underwent an R-Double-CHOP regimen, a dose-intensified immunochemotherapy with or without consolidative high-dose chemotherapy followed by autologous stem cell transplantation. According to immunohistochemical analysis, 10 (25%) patients were categorized as having DEL, showing positivity for MYC (≥40%) and BCL2 (≥50%). The 3 year progression-free survival and overall survival of the DEL group were significantly worse compared with those of the non-DEL group (30% vs. 63%, p = 0.019 and 40% vs. 82%, p = 0.006, respectively). These results suggest that advanced DEL may need discrete treatment strategies.

Acknowledgements

We would like to thank Editage (www.editage.jp) for English language editing. In addition, the authors would like to thank Ms. E. I. and Mr. M. I. for providing excellent technical assistance.

K.M. received lecture fees from Chugai Pharmaceutical Co. Ltd, and Kyowa Hakko Kirin Co., Ltd. N.I. received lecture fees and honoraria from Bristol-Myers K.K. Y.H. received lecture fees from Chugai Pharmaceutical Co. Ltd and Kyowa Hakko Kirin Co., Ltd. M.T. received research funding from Chugai Pharmaceutical Co. Ltd, Kyowa Hakko Kirin Co., Ltd, Bristol-Myers K.K., Shionogi & Co., and Nippon Kayaku Co.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.3109/10428194.2016.1167205.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.